FDA Law Blog: Biosimilars

JUNE 17, 2024

Of the 4,819 facilities in the Site Catalog, 60% manufacture drugs approved under a New Drug Application (NDA), Abbreviated NDA (ANDA), or Biologics License Application (BLA). The Quality Report includes a rundown of what the universe of FDA-registered drug manufacturing sites looks like as included in the CDER Site Catalog.

Pharmaceuticals 59

Pharmaceuticals FDA Production Licensing 59

Agency IQ

JUNE 2, 2023

By harmonizing with the International Electrotechnical Commission, this rule will decrease the regulatory burden on industry and allow the Agency to take advantage of the expertise of the international committees, thereby also saving resources. The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Compliance 40

The Pharma Data

JANUARY 24, 2021

About Combination Clinical Trial The Combination Clinical Trial is an international, multi-center, randomized Phase III study designed to evaluate the efficacy and safety of Toripalimab in combination with Axitinib versus Pembrolizumab as a first-line treatment in patients with unresectable, locally advanced or metastatic mucosal melanoma.

FDA 52

FDA Clinical Trials Trials Treatment 52

The Pharma Data

JULY 27, 2021

We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected.

Production 52

Production Clinical Trials Government Disease 52

The Pharma Data

OCTOBER 29, 2020

Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. The Alzheimer’s Disease International 2019 Alzheimer’s Yearbook estimates that approximately 10 million people in the EU suffer from dementia (excluding Mild Cognitive Impairment). Since October 2017 Biogen and Eisai Co.,

Marketing 40

Marketing Disease Clinical Trials Treatment 40

The Pharma Data

JUNE 30, 2021

Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis ® ) in Europe, Canada, Israel and global markets. Bioeq has in-licensed the exclusive global commercialization rights to FYB201 from the German biosimilar developer Formycon AG. Source link: [link].

Biosimilars 52

Biosimilars International Licensing Licensing 52

The Pharma Data

AUGUST 3, 2021

Product sales increased 3% globally, driven by double digit volume growth across a number of our products including Prolia ® (denosumab), Repatha ® (evolocumab) and our biosimilar products MVASI ® (bevacizumab-awwb) and KANJINTI ® (trastuzumab-anns). AMGEVITA continued to be the most prescribed adalimumab biosimilar in Europe.

Biosimilars 52

Biosimilars Production Treatment FDA 52

Agency IQ

MAY 3, 2024

The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Clinical Trials 40

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Gross margin as a percent of revenue was 79.3

Production 52

Production Marketing Research Government 52

The Pharma Data

APRIL 30, 2021

percent on an operational basis, due to biosimilar competition. net revenues of $999 million and international profit sharing of $269 million. d Reflects profit sharing for Imbruvica international revenues. Global Humira net revenues of $4.867 billion increased 3.5 percent on a reported basis, or 2.6 percent, with U.S.

FDA 40

FDA Production Treatment International 40

Drug Target Review

JULY 6, 2023

3 Furthermore, the act “removes a requirement to use animal studies as part of the process to obtain a license for a biological product that is biosimilar or interchangeable with another biological product.” A new research paper, co-authored by PETA Science Consortium International e.V., Annals of Internal Medicine.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

Drug Discovery World

NOVEMBER 9, 2023

Peter O’Callaghan, PhD, Head of Expression System Sciences, Biologics and Licensing, Lonza, on: ‘Solve bispecific heavy-light chain mispairing with bYlok technology’. Nick Pittman, Marketing Manager, Global Biopharmaceutical Business, Waters Corporation, on: ‘Robust multi-level LC-MS workflows for biosimilar comparability assessment’.

Engineering 130

Engineering Protein Production Therapies Science 130

Agency IQ

SEPTEMBER 29, 2023

Title Type Comments Close Classification Categories for Certain Supplements Under BsUFA III Guidance October 10 Formal Meetings Between the Food and Drug Administration and Sponsors or Applicants of Biosimilar User Fee Act Products Guidance October 10 QTc Information in Human Prescription Drug and Biological Product Labeling Guidance October 10 Postmarketing (..)

FDA 40

FDA Science Regulations Production 40

Agency IQ

FEBRUARY 15, 2024

AgencyIQ has analyzed the agency’s guidance agendas, user fee commitment letters, statutory obligations and international efforts to determine which guidance documents the agency is actively working on this year (and in some cases, in the years ahead as well). We have tried to sort guidance documents by topic area. Priority B List.

FDA 40

FDA Science Biosimilars Production 40

Agency IQ

JUNE 29, 2023

June 2023 Sunlamp Products; Amendment to the Performance Standard (Final Rule) FDA is updating the performance standard for sunlamp products and ultraviolet lamps intended for use in these products to improve safety, reflect new scientific information, and work towards harmonization with international standards.

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

JANUARY 18, 2024

OASH concluded that “there is widespread current experience with medical use of marijuana in the United States” by the licensed healthcare providers for which “such medical use is recognized by entities that regulate the practice of medicine” in these states. to comply with its international treaty obligations. 21 U.S.C. §

FDA 69

FDA FDA Approval Treatment Drugs 69

Agency IQ

DECEMBER 1, 2023

The revisions will update the existing requirements with the specifications of an international consensus standard for medical device manufacturers, ISO 13485:2016. The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

FDA Law Blog: Biosimilars

JUNE 2, 2023

Internal Investigations Under the MDRP, manufacturers must restate incorrect AMPs and best prices and may do so without CMS involvement going back three years from the current quarter. The preamble notes that this information would help ensure that drugs are being used for approved or otherwise medically accepted indications.

Drugs 59

Drugs Regulations Government Vaccine 59

Agency IQ

OCTOBER 27, 2023

and Annex 1 Conference Joel Welch December 18 RAPS RAPS Webcast: FDA Forecast: What’s Next for the FDA in 2024 AgencyIQ Speakers December 21 HL7 REMS Public Call PDUFA Dates expected in November and December PDUFA dates represent the expected date of a regulatory decision by the FDA on a New Drug Application or Biologics License Application.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

FEBRUARY 4, 2021

Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million. Net Revenues of $4.305 Billion and International Profit Sharing of $1.009 Billion; Global Venclexta Net Revenues Were $1.337 Billion. Percent on a Reported Basis, or 13.4

Production 52

Production International Clinical Trials Small Molecule 52

The Pharma Data

SEPTEMBER 16, 2020

We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected.

Clinical Trials 52

Clinical Trials Production Trials Government 52

The Pharma Data

NOVEMBER 9, 2020

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. J Intern Med 2012;272:121–32. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Last accessed: September 2020 ]. 6 Kupczyk M, Wenzel S. 7 Wenzel S.

Trials 52

Trials Production Clinical Trials Government 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Under this rule, CMS will consider all entities, including corporations, partnerships, proprietorships, and other entities treated as a single employer under subsection (a) or (b) of section 52 of the Internal Revenue Code of 1986 as one manufacturer. Phase-in Memorandum at 2.

Compliance 105

Compliance Pharmacy Drugs Licensing 105

The Pharma Data

SEPTEMBER 20, 2020

We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected.

Production 52

Production Clinical Trials Trials Government 52

The Pharma Data

OCTOBER 29, 2020

ALXN2060 (AG10) – Eidos: Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. To participate in the call, dial 866-762-3111 ( USA ) or 210-874-7712 (International), conference ID 6582445 shortly before 8:00 a.m. Eidos is currently evaluating AG10 in a Phase 3 study in the U.S. Eastern Time.

Clinical Trials 40

Clinical Trials Production Trials Licensing 40

The Pharma Data

DECEMBER 21, 2020

Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. 2019;12(5):539-549. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005; 172: 149-160.

Trials 40

Trials Production Clinical Trials Government 40

Agency IQ

SEPTEMBER 1, 2023

MHRA introduces an expanded international recognition procedure, while planning to sunset the current EC reliance pathway Today, the U.K.’s The Access Consortium is a work-sharing initiative involving Australia, Canada, Singapore and Switzerland, to enhance international cooperation and increase regulator capacity. market more quickly.

International 40

International Regulations Production Marketing 40

The Pharma Data

FEBRUARY 8, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. price, patients switching to Toujeo ® and biosimilar glargine competition. driven by Rest of the World sales growth which more than offset biosimilar competition in Europe.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

In Europe, where the product is commercially available in several countries and has a temporary license to be sold in France, sales were €12 million. price, patients switching to Toujeo ® and biosimilar glargine competition. driven by Rest of the World sales growth which more than offset biosimilar competition in Europe.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

Agency IQ

JUNE 2, 2023

Also in 2010, the agency held a two-day public hearing on the subject; following the feedback and lessons from the Brookings Institute and the FDA’s own work, the agency then “narrowed down” the four PMI prototypes to two options, which were further studied by RTI International under a contract with FDA.

FDA 40

FDA FDA Approval Regulations Production 40

The Pharma Data

APRIL 27, 2021

up 60%) driven by increase disease and product awareness as well as adoption of new ISTH (International Society on Thrombosis and Haemostasis) TTP guidelines. net price, increasing usage of Toujeo ® , biosimilar glargine competition and lower sales in Europe (patient stockpilling in the first quarter of 2020). In the U.S.,

Vaccine 52

Vaccine Production FDA FDA Approval 52

FDA Law Blog: Biosimilars

MAY 21, 2024

International Treaty Obligations Prior rescheduling proceedings established that marijuana could not be rescheduled in any less restrictive schedule than schedule II for the U.S. (Thirty-eight states authorize marijuana for specific qualifying medical conditions.) to comply with its treaty obligations.

Regulations 69

Regulations FDA Licensing Licensing 69

The Pharma Data

MAY 4, 2021

Multiple innovative and biosimilar products across our portfolio delivered growth, demonstrating the strength of our business and the depth and breadth of our growth drivers. Internal Medicine. and four additional selling days in international markets. REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *.

Vaccine 40

Vaccine Production FDA Biosimilars 40

FDA Law Blog: Biosimilars

SEPTEMBER 5, 2023

Cannabis in schedule III would require a prescription issued by a DEA-registered, state-licensed practitioner. to comply with its international treaty obligations. Legitimate handlers in the cultivation, manufacturing and distribution chain would have to obtain registrations with DEA. Denial of Petitions at 53,688-89, 53,767-68.

FDA 111

FDA Treatment FDA Approval Drugs 111

Agency IQ

JULY 28, 2023

June 2023 Final Rule Stage Sunlamp Products; Amendment to the Performance Standard FDA is updating the performance standard for sunlamp products and ultraviolet lamps intended for use in these products to improve safety, reflect new scientific information, and work towards harmonization with international standards.

FDA 40

FDA Science Biosimilars Regulations 40

FDA Law Blog: Biosimilars

FEBRUARY 11, 2024

Rescheduling would eliminate a tax burden on cannabis companies, allowing licensed companies to expand investments into state programs and focus on public health in collaboration with law enforcement efforts. States’ regulatory regimes have sought to balance a safe framework with the health and safety risks, especially among youth.

Regulations 59

Regulations Production FDA Approval Marketing 59

FDA Law Blog: Biosimilars

MAY 5, 2024

OASH concluded “there is widespread current experience with medical use in the United States” by licensed healthcare providers for which “such medical use is recognized by entities that regulate the practice of medicine in these states.” The Administrator must control marijuana in the schedule she deems most appropriate to comply with U.S.

FDA 95

FDA Regulations Treatment Licensing 95